Clioquinol Treatment in Familiar Early Onset of Alzheimer’s Disease

C. W. Ritchie; R. Cappai; C. Masters

doi:10.1055/s-2006-931548

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2006; 39(2): 80
DOI: 10.1055/s-2006-931548

Letter

Clioquinol Treatment in Familiar Early Onset of Alzheimer’s Disease

Ibach B et al., Pharmacopsychiatry 2005; 38: 178 - 179
Letter to the EditorC. W. Ritchie¹ , R. Cappai² , C. Masters²

¹Metabolic and Clinical Trials Unit, Department of Mental Health Sciences, University College London, London, UK
²Department of Pathology, University of Melbourne, Melbourne, Australia

Abstract

Full Text

References

1 Ding W Q, Liu B, Vaught J L, Yamauchi H, Lind S E. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005; 65 3389-3395
2 Doraiswamy P M, Finefrock A E. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurology. 2004; 3 431-434
3 Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in Familiar Early Onset of Alzheimer’s Disease. Pharmacopsychiatry. 2005; 38 178-179
4 Prana Biotechnology: http://www.pranabio.com/company_profile/press_releases_item.asp?id = 89.
5 Regland B, Lehman W, Abedini I. et al . Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord. 2001; 12 408-414
6 Ritchie C W, Bush A I, MacKinnon A. et al . Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer’s disease: a pilot phase 2 clinical trial. Arch Neurol. 2003; 60 1685-1691
7 Ritchie C W, Bush A I, Masters C L. Metal-protein attenuating compounds and Alzheimer’s disease. Expert Opin Investig Drugs. 2004; 13 1585-1592

Dr. Craig W. Ritchie

Director of Clinical Trials

University College London

Dept. of Mental Health Sciences

Metabolic and Clinical Trials Unit

Royal Free Campus, Rowland Hill Street

London NW3 2PF

UK

Email: c.ritchie@medsch.ucl.ac.uk